Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Qiang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2707-0258; OpenAlex author ID A5100381902. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 10

  1. Exploring prognostic and immunological characteristics of pancreatic ductal adenocarcinoma through comprehensive genomic analysis of tertiary lymphoid structur… Co-author DOI 10.1007/s00432-024-05824-0↗
  2. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a prop… Co-author DOI 10.1080/14737140.2024.2347513↗
  3. Oral microbiome-driven virulence factors: A novel approach to pancreatic cancer diagnosis. Co-author DOI 10.17305/bb.2023.9934↗
  4. An anti-bacterial and anti-cancer fibrous membrane with multiple therapeutic effects for prevention of pancreatic cancer recurrence. Co-author DOI 10.1016/j.bioadv.2022.212831↗
  5. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-20-0365↗
  6. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0597↗
  7. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Co-author DOI 10.1158/0008-5472.can-19-0761↗
  8. Effects of ME3 on the proliferation, invasion and metastasis of pancreatic cancer cells through epithelial-mesenchymal transition. Co-author DOI 10.4149/neo_2019_190119n59↗
  9. ZIP4 silencing improves bone loss in pancreatic cancer. Co-author DOI 10.18632/oncotarget.4667↗
  10. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines. Co-author PMID 21362344↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hao Hu · 2 shared papers, 2024 · strength 0.50
  2. Zhenyu Wu · 1 shared paper, 2024 · strength 0.28
  3. Yuan Hong Gao · 1 shared paper, 2024 · strength 0.28
  4. Xuemin Zeng · 1 shared paper, 2023 · strength 0.22
  5. Xiao Hua Yuan · 1 shared paper, 2023 · strength 0.22
  6. Zhenyu Wu · 1 shared paper, 2024 · strength 0.22
  7. Leslie A. Parsels · 2 shared papers, 2019–2021 · strength 0.21
  8. Theodore Steven Lawrence · 2 shared papers, 2019–2021 · strength 0.21
  9. Meredith Ann Morgan · 2 shared papers, 2019–2021 · strength 0.21
  10. Xin Zhao · 1 shared paper, 2022 · strength 0.17
  11. Qingyan Zhao · 1 shared paper, 2019 · strength 0.14
  12. Carl G. Engelke · 1 shared paper, 2021 · strength 0.13
  13. Avnish Kapoor · 1 shared paper, 2020 · strength 0.09
  14. Jianhua Zhang · 1 shared paper, 2020 · strength 0.09
  15. Ronald Anthony Depinho · 1 shared paper, 2020 · strength 0.09
  16. Raghu Kalluri · 1 shared paper, 2020 · strength 0.09
  17. Pingping Hou · 1 shared paper, 2020 · strength 0.09
  18. Marina Pasca di Magliano · 1 shared paper, 2019 · strength 0.08
  19. Jiaqi Shi · 1 shared paper, 2019 · strength 0.08
  20. Timothy L. Frankel · 1 shared paper, 2019 · strength 0.08
  21. Zhao‐Shen Li · 1 shared paper, 2015 · strength 0.05
  22. Min Li · 1 shared paper, 2015 · strength 0.05
  23. Jingxuan Yang · 1 shared paper, 2015 · strength 0.05
  24. Xiaotian Sun · 1 shared paper, 2015 · strength 0.05
  25. Courtney W. Houchen · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.